Breaks Categories: News

FridayDec 03, 2021 11:29 am

PsychedelicNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) to Present at 2nd Annual H.C. Wainwright Psychedelics Conference

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today announced that it will present at the Second Annual H.C. Wainwright Psychedelics Conference. The event is slated to be held virtually on Dec. 6, 2021. Tryp’s chairman and CEO Greg McKee will provide an overview of the business and its pipeline, including the upcoming phase 2a clinical trials in fibromyalgia, phantom limb pain, binge eating disorder and other indications. McKee's presentation will be available on-demand through the H.C. Wainwright conference portal beginning at 7:00 a.m. ET. on Monday, Dec.…

Continue Reading

FridayDec 03, 2021 9:30 am

PsychedelicNewsBreaks – FSD Pharma Inc.’s (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9) Lucid-MS Featured in InvestmentPitch Video, CEO to Present at H.C. Wainwright Psychedelics Virtual Conference

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, today shared preclinical data demonstrating the potentially disease-modifying effects of Lucid-MS, its lead drug candidate for the potential treatment of multiple sclerosis in the animal models of MS. According to the update, InvestmentPitch.com has produced a video discussing the news. Based on over a decade of research, Lucid-MS is a patented neuroprotective new chemical entity that affects protein citrullination and myelin structure, which are associated with the severity of MS lesions. FSD Pharma has released a video…

Continue Reading

ThursdayDec 02, 2021 11:31 am

PsychedelicNewsBreaks – Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Plans Opening of Two Additional Ketamine Wellness Centers

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, announced that subsidiary Ketamine Wellness Centers (“KWC”) is planning to open new clinics in Salt Lake City, Utah, and Reno, Nevada; the clinics are slated to open by February 2022. The new clinics will bring the total of KWC locations to 12; the company currently has 10 ketamine infusion treatment clinics in eight different states and is positioned as the largest chain of wellness centers in the country. The Utah location will be one of KWC’s largest clinics, and the Reno clinic is strategically…

Continue Reading

ThursdayDec 02, 2021 10:00 am

PsychedelicNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Receives Green Light from FDA for Clinical Study in Fibromyalgia

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today announced its receipt of confirmation from the U.S. Food and Drug Administration (“FDA”) that its review of Tryp’s Investigational New Drug (“IND”) application is complete and that the company may proceed with its clinical study in fibromyalgia. The trial, which the company expects to initiate in 2022, is being conducted with Kevin Boehnke, Ph.D. from the University of Michigan and will evaluate Tryp’s oral formulation of synthetic psilocybin, TRP-8802, in combination with psychotherapy. “The upcoming phase 2a study with…

Continue Reading

ThursdayDec 02, 2021 8:30 am

PsychedelicNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9) Shares Preclinical Data Demonstrating Positive Effects of Lucid-MS in Treating Multiple Sclerosis

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, today shared preclinical data, supported by an explanatory video, demonstrating the potentially disease-modifying effects of Lucid-MS, the company’s lead drug candidate for the potential treatment of multiple sclerosis (“MS”), in the animal models of MS. “Lucid-MS has demonstrated the potential to prevent the degradation and help re-establish myelin, which is evidenced by the functional recovery of mice as well as immunohistochemistry in this study, and several other studies in preclinical animal models,” said Dr. Lakshmi P. Kotra,…

Continue Reading

WednesdayDec 01, 2021 2:38 pm

PsychedelicNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Eager to Initiate ‘One of the First Evaluations of Psilocybin to Treat Fibromyalgia’

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) recently submitted an Investigational New Drug (“IND”) application to the U.S. FDA to evaluate its TRP-8802 clinical candidate in a phase 2a clinical trial to explore psilocybin-assisted therapy’s safety and preliminary effectiveness among individuals dealing with fibromyalgia. The study, which is being conducted in collaboration with the University of Michigan, spearheaded by Kevin Boehnke, Ph.D., will involve 20 fibromyalgia patients and include various exploratory endpoints, particularly given the high prevalence of comorbidities that include anxiety, depression, poor sleep quality and other conditions. Tryp expects to initiate the study in 2022, subject to a favorable…

Continue Reading

TuesdayNov 30, 2021 1:07 pm

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces Key FDA Approvals, Participation in Psychedelics Conference

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), has received authorization from the U.S. Food and Drug Administration (“FDA”) for an investigator-initiated, randomized, placebo-controlled phase 2 clinical trial; the trial is designed to evaluate psychedelic-assisted psychotherapy with psilocybin for frontline clinicians experiencing COVID-related distress. The company noted that the primary investigator for the trial, Dr. Anthony Back, received an investigational new drug ("IND") approval letter from the FDA, authorizing the trial. In addition, the study has received Institutional Review Board (“IRB”) approval at the University of Washington. Cybin also announced that CEO Doug Drysdale…

Continue Reading

MondayNov 29, 2021 11:48 am

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Notes Adelia Milestone Achievements

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), has reported that its wholly controlled subsidiary, Adelia Therapeutics Inc., has achieved key milestones. The milestones were outlined in the agreement between Cybin, Cybin Corp., Cybin US Holdings Inc. and the previous shareholders of Adelia. Based on the agreement, 31,721.5 class B common shares of the company will be issued to Adelia shareholders as a result of relevant milestones being met. Adelia develops medicinal psychedelics designed to provide improved dosing efficacy and therapeutic indices that address unmet medical needs. The company’s primary focus is on the…

Continue Reading

TuesdayNov 23, 2021 10:29 am

PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Awards Grant for Psychedelic Treatment Clinic to Benefit Underserved Communities

Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” today announced it has awarded a grant for the first psychedelic treatment clinic at Lenox Hill Hospital, part of Northwell Health, to serve marginalized and underserved communities on the Upper East Side of Manhattan, New York. According to the update, the program aims to become one of the first hospital-based clinical sites to offer psychedelic medicine in the United States. “It’s time for psychedelic medicine to climb down from the ivory tower and into the community,” said Dr. Alex Belser, chief clinical officer of Cybin.…

Continue Reading

ThursdayNov 18, 2021 10:53 am

PsychedelicNewsBreaks – Delic Holdings Inc. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Unveils First-of-Its-Kind Family Support & Education Program

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, has announced that its chain of Ketamine Wellness Clinics (“KWC”) will be offering the industry’s first support and education program designed to support the family and loved ones of its patients. KWC, the country’s largest chain of wellness centers that provide ketamine treatments, launched its Family Support & Education program today; the free program is designed by medical professionals to help families, significant others and loved ones provide valuable support to patients who choose ketamine infusion treatments. In announcing the program,…

Continue Reading